Enrichment of cancer-predisposing germline variants in adult and pediatric patients with acute lymphoblastic leukemia

• Published in: Scientific reports Vol. 12; no. 1; p. 10670
• Main Authors: Douglas, Suvi P. M., Lahtinen, Atte K., Koski, Jessica R., Leimi, Lilli, Keränen, Mikko A. I., Koskenvuo, Minna, Heckman, Caroline A., Jahnukainen, Kirsi, Pitkänen, Esa, Wartiovaara-Kautto, Ulla, Kilpivaara, Outi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.06.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/208/1516; 631/208/212/2166; 631/208/212/2301; 631/67/1990/283/2125; Acute lymphoblastic leukemia; Genetic counseling; Genetic screening; Genetics; Hematopoietic stem cells; Humanities and Social Sciences; Leukemia; Leukemogenesis; Medicin och hälsovetenskap; multidisciplinary; Patients; Pediatrics; Science; Science (multidisciplinary); Stem cell transplantation; Stem cells; Toxicity
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-14364-x

Despite recent progress in acute lymphoblastic leukemia (ALL) therapies, a significant subset of adult and pediatric ALL patients has a dismal prognosis. Better understanding of leukemogenesis and recognition of germline genetic changes may provide new tools for treating patients. Given that hematopoietic stem cell transplantation, often from a family member, is a major form of treatment in ALL, acknowledging the possibility of hereditary predisposition is of special importance. Reports of comprehensive germline analyses performed in adult ALL patients are scarce. Aiming at fulfilling this gap of knowledge, we investigated variants in 93 genes predisposing to hematologic malignancies and 70 other cancer-predisposing genes from exome data obtained from 61 adult and 87 pediatric ALL patients. Our results show that pathogenic (P) or likely pathogenic (LP) germline variants in genes associated with predisposition to ALL or other cancers are prevalent in ALL patients: 8% of adults and 11% of children. Comparison of P/LP germline variants in patients to population-matched controls (gnomAD Finns) revealed a 2.6-fold enrichment in ALL cases (CI 95% 1.5–4.2, p  = 0.00071). Acknowledging inherited factors is crucial, especially when considering hematopoietic stem cell transplantation and planning post-therapy follow-up. Harmful germline variants may also predispose patients to excessive toxicity potentially compromising the outcome. We propose integrating germline genetics into precise ALL patient care and providing families genetic counseling.